PMID-39623223 – Chimeric Senolytic Peptide in Tumorigenesis and Aging
Ming X et al. "A chimeric senolytic peptide enhances immune clearance of senescent cells in fibrosis, tumorigenesis, and aging," Nature Aging, 2025;5:xxx-xxx. doi:10.1038/s43587-024-00750-9
Quick Reference
| Property | Value |
|---|---|
| PMID | 39623223 |
| DOI | 10.1038/s43587-024-00750-9 |
| Year | 2025 |
| Journal | Nature Aging |
| Study Type | Animal in vivo + In vitro |
| Evidence Level | V |
| Sample | Mouse models of fibrosis, cancer, and aging |
| Peptide(s) Studied | Novel uPAR-binding chimeric senolytic peptide (next-generation senolytic) |
Key Findings
- A novel chimeric senolytic peptide was engineered to bind uPAR (urokinase-type plasminogen activator receptor), which is highly expressed on senescent cells
- Unlike FOXO4-DRI which directly triggers apoptosis, this peptide enhances immune-mediated clearance of senescent cells by flagging them for NK cell and macrophage recognition
- Demonstrated efficacy across three disease contexts: organ fibrosis, tumorigenesis, and age-related pathology in mouse models
- In fibrosis models, the peptide reduced collagen deposition and restored organ architecture
- In cancer models, clearance of senescent cells from the tumor microenvironment reduced SASP-driven tumor promotion and improved anti-tumor immunity
- In aged mice, treatment improved physical function, reduced inflammatory markers, and extended healthspan metrics
- Published in Nature Aging, establishing this as a next-generation approach to senolytic therapy
Study Design
Preclinical study using multiple mouse models. Chimeric peptide was designed with a uPAR-binding domain fused to an immune-activating sequence. Tested in: (1) bleomycin-induced lung fibrosis model, (2) chemically induced and transplantable tumor models, and (3) naturally aged mice (20+ months). Readouts included senescent cell quantification, immune cell infiltration, organ function, physical performance, and survival.
Limitations
- Entirely preclinical — no human safety or efficacy data
- uPAR expression is not exclusive to senescent cells; potential for off-target immune activation against uPAR-expressing normal cells
- The immune-mediated mechanism depends on competent immune function, which may be impaired in the elderly or immunosuppressed cancer patients
- Long-term effects of immune-targeted senescent cell clearance unknown
- Comparison with existing senolytics (FOXO4-DRI, dasatinib+quercetin) not performed
Clinical Relevance
This Nature Aging publication represents the cutting edge of senolytic peptide research. The immune-mediated approach is mechanistically distinct from FOXO4-DRI's direct apoptosis induction, potentially offering broader applicability and engaging the immune system for sustained surveillance. The demonstrated efficacy across fibrosis, cancer, and aging contexts suggests a versatile therapeutic platform. For the Ageless Pep Academy, this paper illustrates the evolution of the senolytic field from first-generation (FOXO4-DRI) to next-generation approaches.
Related
#research #animal-in-vivo #evidence-level-V #cancer